Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 1999

View Archived Issues

Company Profile: Ranbaxy

Positive results shown in phase III interim analysis of Neutralase

Discovery receives Cystic Fibrosis Foundation grant for SuperVent

New company formed to develop therapeutic proteins with prolonged activity

Mallinckrodt to market Palatin Technologies' infection imaging agent

Long-term Aricept treatment improves cognitive function, prevents decline in patients with AD

Xoma: Q2 1999 highlights

Gliatech's IDE for ADCON-L approved by FDA

Diatide highlights Q2 1999 activities

Anesta seeks approval for Actiq in the U.K.

ImmGenics' SLAM technology presented at conference

EUK-134 protects against neuronal damage in seizure model

Known anti-HIV compound also shows potential in treating immune disorders

Zenyaku Kogyo will develop and market novel psoriasis treatment in Japan

RWJ-56110: first report of a new antithrombotic targeting the PAR-1 receptor

Yakult Honsha discloses potent and water-soluble taxane derivatives

Novel antimycotic agent TRK-2999 isolated from a fungal strain

SRL-172 shows promising initial results in phase I/II asthma trial

Clinical trials of SRL-172 in lung cancer are progressing

Pfizer investigates ORL1 agonists with analgesic activity in rodent models

Neurokinin receptors with broad potential utility discovered at Schering-Plough

Sumitomo research provides new interferon inducers

Chugai continues to investigate new vitamin D compounds

Sanofi researchers modify heparin structure to improve on therapeutic properties

Factor Xa inhibitor HMR-2906 is more effective and safer than hirudin in dog model of thrombosis

Servier's novel approach to antiplatelet therapy: dual TP antagonists/NO donors

Agouron commences phase III trial of prinomastat for treatment of lung cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...